WhatsApp
Facebook
Instagram
X (Twitter)
YouTube
LinkedIn

24/7 Customer Support

cymevene ganciclovir for injection cytomegalovirus infection and cmv 0

Description

 Indication & Scope

Cymevene® Ganciclovir for Injection provides treatment and long-term suppression of cytomegalovirus infection in immunocompromised patients; prevention of CMV disease after organ transplantation.

  • Mechanism: Nucleoside analog that inhibits CMV DNA polymerase to block viral replication and genome assembly.
  • Drug class: Anti-cytomegalovirus nucleoside analog injectable antiviral agent.
  • Clinical use: Acute treatment of active CMV retinitis, pneumonia and gastrointestinal infection in immunodeficient patients; preventive prophylaxis for transplant recipients.
Specification
Generic Name Ganciclovir for Injection
Brand Name Cymevene
Ingredient Ganciclovir
Dosage Form Injection
Package 0.5g*1 vial/box
Conditions Treated Active cytomegalovirus infection in immunocompromised populations; post-transplant CMV prophylaxis
Taboos Severe hypersensitivity to ganciclovir; severe pre-existing neutropenia or thrombocytopenia
Place of origin Via Appia Km. 65,561 04013 Latina Scalo LT Italy
Prescription type Prescription-only
Storage Conditions Unopened vials stored at 15°C–30°C; reconstituted solution used within 24 hours
Manufacturer BSP Pharmaceuticals S.p.A.
Registration Authority National Medical Products Administration (NMPA), China
Approval number HJ20130374
Approval Date Oct 10, 2023
Shelf Life 24 months

How to use ?

Recommended Dose: Induction therapy: 5mg/kg intravenous infusion every 12 hours for 14–21 days; maintenance: 5mg/kg once daily.

 

Time: Fixed 12-hour intervals for induction infusion, regardless of meal timing.

 

Instructions for use: Reconstitute powder with sterile solvent before dilution for slow intravenous drip; monitor complete blood count daily due to myelosuppression risk.

 

Interaction: Concurrent myelosuppressive drugs drastically increase leukopenia and thrombocytopenia risks.

 

Side effects:

1. Common: severe neutropenia, thrombocytopenia, fever, injection site inflammation.

2. Rare severe: irreversible bone marrow suppression, renal injury.

Important Notice

This product should be administered only by qualified healthcare professionals in accordance with the approved prescribing information and local clinical guidelines. Dosage and administration may vary depending on patient condition, indicatiaon, and regional regulatory requirements.

Packaging & Shipping

Packaging

Original manufacturer’s packaging with secure export carton. Customized export packaging is available upon request.

Shipping Methods

Express Courier (EMS, DHL, FedEx, UPS), Air Freight, and Sea Freight. Cold-chain transportation is available for products requiring temperature-controlled logistics.

Export Support

Certificate of Analysis

GMP Certificate

Commercial Invoice

Packing List & CPP

Cold Chain Logistics

Customs Documentation

Scientific and regulatory sources

1.WHO References
2.NMPA
3.FDA
4.EMA

FAQ

What two core clinical scenarios cover the approved indications for injectable Ganciclovir for Injection?

The medicine treats active cytomegalovirus infection in immunocompromised groups and provides preventive prophylaxis for organ transplant recipients.

What most frequent and dangerous adverse reaction requires daily blood testing during intravenous Ganciclovir for Injection?

Severe bone marrow suppression leading to sharp drops in white blood cells and platelets requires routine blood count monitoring.

What type of patients forms the primary applicable population for Ganciclovir for Injection injectable anti-CMV medication?

Immunocompromised patients including transplant recipients and immunodeficient individuals are the core treatment population.

What risk is greatly amplified when Ganciclovir for Injection is combined with other myelosuppressive medicines?

Combined use drastically increases the risk of severe, potentially irreversible bone marrow suppression.

Cymevene® | Ganciclovir for Injection | Cytomegalovirus Infection/CMV | DengYueRX

INN: Ganciclovir for Injection
Indications: Cytomegalovirus infection/CMV
Dosage Form: Injection
Strength: 0.5g/vial

Original price was: $102.76.Current price is: $87.34.

Low MOQ

WHO-GMP

Worldwide Delivery

Compliance and Regulatory Documents

Related Products

Scroll to Top

Your Cart

Your Cart

Your Cart is Empty

Start Shopping
Continue Shopping
Payment Details
Sub Total $0.00